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Abstract
Background: Economic theory provides the philosophical foundation for valuing costs in judging medical and
public health interventions. When evaluating smoking cessation interventions, accurate data on costs are essential
for understanding resource consumption. Smoking cessation interventions, for which prior data on resource
costs are typically not available, present special challenges. We develop a micro-costing methodology for
estimating the real resource costs of outreach motivational interviewing (MI) for smoking cessation and relapse
prevention among low-income pregnant women and report results from a randomized controlled trial (RCT)
employing the methodology. Methodological standards in cost analysis are necessary for comparison and
uniformity in analysis across interventions. Estimating the costs of outreach programs is critical for understanding
the economics of reaching underserved and hard-to-reach populations.
Methods: Randomized controlled trial (1997-2000) collecting primary cost data for intervention. A sample of
302 low-income pregnant women was recruited from multiple obstetrical sites in the Boston metropolitan area.
MI delivered by outreach health nurses vs. usual care (UC), with economic costs as the main outcome measures.
Results: The total cost of the MI intervention for 156 participants was $48,672 or $312 per participant. The total
cost of $311.8 per participant for the MI intervention compared with a cost of $4.82 per participant for usual
care, a difference of $307 ([CI], $289.2 to $322.8). The total fixed costs of the MI were $3,930 and the total
variable costs of the MI were $44,710. The total expected program costs for delivering MI to 500 participants
would be 147,430, assuming no economies of scale in program delivery. The main cost components of outreach
MI were intervention delivery, travel time, scheduling, and training.
Conclusion: Grounded in economic theory, this methodology systematically identifies and measures resource
utilization, using a process tracking system and calculates both component-specific and total costs of outreach MI.
The methodology could help improve collection of accurate data on costs and estimates of the real resource costs
of interventions alongside clinical trials and improve the validity and reliability of estimates of resource costs for
interventions targeted at underserved and hard-to-reach populations.
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Background
Economic theory provides the philosophical foundation
for valuing costs in judging medical and public health
interventions. Resources used in, and saved as a result of,
medical and public health programs must be measured in
terms of their monetary costs to understand the overall
implications of such interventions. Under economic the-
ory, the opportunity cost of a resource - or its value in its
next best or alternative use - is the real cost of that resource
to society. Under ideal circumstances (e.g., perfect compe-
tition, absence of market failures such as externalities and
public goods and absence of market distortions such as
insurance) the price of a resource can be taken as its
opportunity cost. However, medical and public health
programs rarely operate under ideal market conditions.
Thus, we cannot always rely solely on prices to value all
resources in the economic evaluation of medical and pub-
lic health interventions, although prices are almost always
used for cost estimates. Rather, we need a systematic
methodology for measuring costs grounded in the theory
and process of identifying, estimating and valuing
resource costs. This method can be described as micro-
costing.
Despite recent work on economic evaluation in clinical
trials [1], which focuses, for example, on econometric
techniques for the analysis of cost distributions, little, if
any, research has been conducted on micro-costing in
health and medicine, particularly in conjunction with ran-
domized controlled trials (RCT). Cost analyses in many
areas of public health and medicine, including smoking
cessation, have not typically been conducted uniformly
and standardized so as to compare cost estimates across
studies. Many have not included future costs, patient time
and travel, or set-up and implementation costs. Incom-
plete and inadequate cost analyses can have a significant
effect on final cost analyses (especially where real costs are
underestimated), and on cost-effectiveness and cost-util-
ity analyses. Cost analyses require standardized method-
ology as recommended by the Panel on Cost-Effectiveness
in Health and Medicine [2] (hereinafter, the Panel). The
lack of standardized or uniform methods in estimating
costs is problematic because it limits our ability to deter-
mine which resources allocated to medical and public
health programs are used more equitably and efficiently.
This article aims to address these gaps in the literature.
Currently available economic evaluations of behavioral
counseling services for smoking cessation provide limited
evidence on costs to determine optimal resource alloca-
tion strategies. With some notable exceptions, few studies
have been performed in accordance with U.S. Panel on
Cost-Effectiveness in Health and Medicine recommenda-
tions grounded in economic theory. While such limita-
tions hinder comparisons among programs, they also
represent an opportunity for future analyses to better
adhere to sound and consistent methodologies. A lack of
economic studies is common in public health and medi-
cine, however, especially in the area of prevention services
[3]. Despite these limitations, efforts to sort out the finer
methodological challenges in the cost elements of eco-
nomic evaluation will eventually lead to more uniformity
in reporting. For example, efforts to enumerate cost cate-
gories will improve the generalizability and comparability
of the results of economic evaluations. In combination
with established standards, such efforts will help in the
development of an analytic framework for making future
studies more comparable. Moreover, efforts to design and
conduct economic evaluations of drug abuse treatment,
smoking cessation, and relapse prevention, would ideally
be planned prospectively and apply standardized
methods.
Smoking imposes a significant economic burden on soci-
ety, and smoking cessation can improve both the quantity
and quality of life at low costs [4,5]. When evaluating
smoking cessation interventions, accurate data on costs
are essential for understanding resource consumption.
Smoking cessation interventions, for which prior data on
resource costs typically are not available, present chal-
lenges. Outreach programs, in particular, present special
challenges because resources are concentrated in the field;
yet, estimating the costs of outreach programs is critical
for understanding the economics of targeting underserved
and hard-to-reach populations. Therefore, we developed a
methodology for collecting and providing cost data for
outreach smoking cessation and relapse prevention pro-
grams such as motivational interviewing (MI). MI is a par-
ticipant-tailored technique, which explores perceptions
and concerns about smoking, clarifies conflicting motiva-
tions, focuses on participants' social contexts, and pro-
vides support and skills training. It aims to reduce
household levels of nicotine, increase readiness to quit,
and lower relapse rates. MI was originally developed in
the specialist setting for use with chronic alcoholics and,
over the past several years, has increasingly been adapted
for use in public health settings [6,7]. Although MI is
increasingly being adapted and used in addiction
research, few, if any, studies have measured the costs of
delivering this technique in outreach settings.
In a randomized controlled trial (1997-2000), we com-
pared MI on an outreach basis (N = 156) with Usual Care
(UC) (N = 146) among low-income pregnant women in
Boston. During an average of three home visits, a nurse
delivered the MI intervention and built a relationship
with the participant. The MI components were tailored to
each participant's stage of readiness.BMC Pregnancy and Childbirth 2009, 9:46 http://www.biomedcentral.com/1471-2393/9/46
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Because this program consumed a considerable amount
of professional time (e.g., for intervention training, prep-
aration, scheduling, and delivery, and for travel to and
from the intervention delivery site), it was important to
precisely estimate its true costs. Therefore, we used micro-
costing, which directly enumerates and subsequently val-
ues each input consumed for each particular participant.
This approach's level of detail is especially important
when personnel time or training account for a major por-
tion of an intervention's costs. Because it is difficult to ret-
rospectively create records of personnel time expended
during a behavioral intervention, these data must be
tracked during program delivery. For outreach programs,
travel time and mileage must also be collected prospec-
tively. To capture these details, we developed a process
tracking system.
When assessing the full costs of smoking cessation and
relapse prevention programs, it is also important to
account for potential future resource use or savings that
might result from the intervention. Published estimates of
net lifetime additional medical costs for smokers [8-10]
and net smoking-attributable medical costs for neonatal
intensive care, chronic medical conditions, and acute con-
ditions during the first year of life [11] provide evidence
for the significance of these costs. Gross-costing (e.g., cost
estimate of typical costs for a good or service) of clinical
events prevented is more suitable for this purpose, but its
estimates should be included in sensitivity analyses to
assess their importance to the overall analysis [2].
When the Panel on Cost-Effectiveness in Health and Med-
icine recommended micro-costing in the late 1990s [2], it
suggested breaking the production and delivery of an
intervention into discrete work-steps, which could be ana-
lyzed separately; however, it gave few guidelines on how
to implement a micro-costing study, in general, and no
guidelines or procedures on how to do so in particular
studies. For each step, all inputs, including personnel and
patient time and supplies and equipment, are inventoried
and measured. The costs of each step are summed to
determine the intervention's total cost [2]. The straightfor-
ward micro-costing methodology developed here was
grounded in economic theory and undergirded by the
Panel's recommendations, which we modified and
applied to an outreach MI program. As an input to cost-
effectiveness analyses (CEA) and cost-benefit analyses
(CBA), this methodology could enable benefits to be
weighed against costs to facilitate rational allocation deci-
sions. Cost estimation and analysis need not, however, be
confined to use in CEA or CBA, but may be relevant as a
stand-alone measure of economic impact, as an element
of cost-minimization analysis (CMA) and as a component
of a larger theory of health and social justice [12].
Methods
Recruitment, design, and sample of randomized controlled 
trial
Potential study participants were recruited from a large
number of community-based health care practices and
community health care centers that provided prenatal
care. To be eligible, women had to be less than 28 weeks
pregnant, speak English or Spanish, and be either current
smokers or recent quitters (e.g., quit during previous three
months). They also could not be in drug addiction treat-
ment. During routine prenatal visits, health care providers
described the study and assessed women's interest in par-
ticipating. Study personnel then received contact informa-
tion and called interested women for further explanation
of the study. Trained research assistants visited the women
in their homes to answer questions, obtain informed con-
sent, conduct the baseline survey, and complete other
study assessments. The health care providers referred 549
women to the study. Of those, 65 did not meet eligibility
requirements, and 68 could not be located. Of the remain-
ing 416 women, 114 refused participation. The final sam-
ple at baseline was 302 pregnant women (73% of known
eligible women).
After the 302 women gave their consent and completed
the baseline assessment, they were randomly assigned to
either UC or MI. Follow-up assessments were conducted
10 weeks after baseline (prenatal assessment) and 4 to 6
months after the baby's birth (postnatal assessment). At
each assessment visit, passive sampling dosimeters were
placed in the home (kitchen and living room) for 7 days
to assess air nicotine concentrations. Feedback about nic-
otine levels was provided as part of the MI intervention.
Intervention conditions
Usual care
After UC participants completed the baseline survey, a let-
ter was sent to their prenatal care providers indicating the
patient's study participation and recommending that the
provider discuss the patient's smoking with her. A descrip-
tion of the study, a tip sheet for providers based on the
Agency for Healthcare Research and Quality (AHRQ)
guidelines [13] and a pamphlet describing ways of dealing
with nicotine withdrawal symptoms were included with
the letter. Participants in this condition received their
usual prenatal care from their providers.
Motivational interviewing
In addition to their usual care, MI participants received
monthly visits from a Public Health Nurse until one
month post-partum. The intervention was designed to
address social contextual factors that might influence
responses to the smoking intervention. The nurse was
available to help with all aspects of pregnancy, includingBMC Pregnancy and Childbirth 2009, 9:46 http://www.biomedcentral.com/1471-2393/9/46
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prenatal education, gaining needed social services, smok-
ing cessation and secondhand smoke reduction.
The intervention was based on motivational interviewing
[14], which emphasizes the woman's choice, personal
responsibility for change, and enhancement of self-effi-
cacy. The MI component was designed to increase motiva-
tion and self-efficacy for smoking cessation and to provide
support and skills-training. Thus, the sessions explored
the participants' perceptions and concerns about smok-
ing, increasing their awareness of the pros and cons of
smoking and clarifying conflicting motivations governing
decision-making. The goals of the MI session were: (1) to
provide information about the impact of smoking on the
mother and fetus and the impact of secondhand smoke
on newborns; (2) to help participants re-evaluate their
smoking behavior; (3) to increase perceived self-efficacy
for the ability to quit smoking; (4) to educate the partici-
pants about mechanisms for reducing secondhand smoke
exposure and to set goals for changing smoking habits;
and (5) to provide feedback about the impact of changes
on household nicotine levels. These MI components were
tailored to each participant's stage of readiness.
The first counseling session focused on increasing motiva-
tion, in part by addressing ambivalence associated with
the decision to quit smoking. The nurses began the coun-
seling session by presenting results from household nico-
tine assessments. If the woman was interested, the nurse
discussed ways to either reduce the nicotine levels in the
home or, if levels were low, ways to prevent them from
increasing. Smoking cessation was discussed with women
who were interested. Additionally, the nurses worked with
the participants on setting goals in other areas of their
lives (e.g., employment, education, parenting skills, social
service needs). When appropriate, the relationship
between these other goals and smoking was explored. The
first counseling session placed a strong emphasis on goal
setting. Progress toward those goals was the focus of the
subsequent intervention visits.
Micro-costing methodology
The theory and process of valuing costs through a micro-
costing methodology rests on a three-step approach: iden-
tification, measurement, and valuation of resources used.
While the Panel recommended following this theory and
process, it provided no guidelines on implementing a
micro-costing study, in general, and no procedures on
how to do so in specific studies. Because micro-costing
uses primary data on the exact number and type of
resources consumed by each participant, it is most accu-
rate when it tracks resource consumption as it occurs,
thereby enhancing the validity and reliability of cost esti-
mates. Once resource utilization is measured, the quantity
of each type of resource consumed is multiplied by unit
costs, and the results are summed to obtain total compo-
nent-specific costs and overall cost. Total and component-
specific costs can then be divided by the number of partic-
ipants to determine expected costs per participant.
The Panel also recommended that future costs and savings
attributable to an intervention be included in cost analy-
ses from the societal perspective, in addition to micro-
costing of intervention costs. Many interventions, espe-
cially preventive ones, for example, can result in future
savings that offset initial costs. Analyses performed from
the perspective of a provider or payer would include only
those costs and savings that they bear or realize. Thus, in
this micro-costing study, we include the patient's costs as
well as the providers' costs and we conceptualize future
savings that could offset initial costs. We conclude with
sensitivity analyses of the robustness of these estimates to
changes in key cost components.
Step 1: Identifying resources used (component 
enumeration)
In step 1, it is important to thoroughly delineate all inputs
that might be affected by the intervention so as to account
for the cost of each component. This first step involves the
identification of resources used in the "production proc-
ess" of the intervention. Each "work step" in the produc-
tion process is then described in conjunction with the
relevant cost components. This step may also be called
component enumeration, whereby each factor involved
in the "production" of the intervention is identified and
fixed costs (that do not vary with volume) are separated
from variable costs (that do vary with volume). The Panel
recommended that incremental costs (those required to
produce an additional unit of service) rather than average
costs (the total cost of an intervention divided by the units
of services produced) be collected and analyzed.
As shown in Table 1, the costs for outreach MI can be rep-
resented by a three-way partition of cost categories: (1)
set-up or implementation costs, including the costs of
staff time and training materials; (2) time-dependent pro-
gram costs (such as administrators' salaries or training
costs for staff turnover), which are independent of the
number of participants in a program, but incurred for as
long as a program operates; and (3) variable program
costs, which vary with the number of participants and
include staff time spent interviewing participants, partici-
pant time, transportation, and consumables. Using this
classification enables analysts to extrapolate to programs
of different sizes.
Table 2 lists the cost components for outreach MI: (1)
training costs (including time and travel for trainers and
trainees, teaching materials, hand-outs and overheads,
training manuals, refreshments); (2) personnel costsBMC Pregnancy and Childbirth 2009, 9:46 http://www.biomedcentral.com/1471-2393/9/46
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(scheduling, preparation, and delivery of intervention,
travel time, distribution of intervention materials, collec-
tion of biochemical assessments included in the interven-
tion); (3) travel costs (including mileage to and from
intervention site); (4) patient/participant time during MI;
(5) intervention materials (including printed materials);
and (6) analysis of nicotine samples (used as a compo-
nent of the intervention).
To determine the amount of personnel time involved in
the intervention, we had to describe the work-steps
involved. They included scheduling and follow-up, prep-
aration, travel, and intervention delivery (counseling ses-
sions). The process tracking form served as a generic flow
chart for these steps.
We did not include the clinics' overhead costs (e.g., laun-
dry, heating expenses) because they were similar in the
intervention (MI) and control (UC) groups and as an out-
reach program, whereby the set-up and delivery of the
intervention occurred "off-site," the similar overhead
costs would likely be minimal. Because the participants
were interviewed at home, clinic and hospital operating
expenses (facilities costs) were not relevant. Neither were
productivity costs [2] (participant work time lost due to
morbidity or mortality), though participant time spent
receiving MI was included.
Extending the cost analysis to the societal perspective
would include net resource costs: (1) the intervention
costs described above; (2) cost savings for neonatal inten-
sive care, chronic medical conditions, and acute condi-
tions during the first year of life; and (3) cost savings for
maternal health care (e. g., reductions in lifetime medical
expenditures for cardiovascular and lung diseases).
Step 2: Measuring resource use (the process tracking 
system)
To enhance the reliability and validity of our cost data, we
measured and valued all inputs consumed as the program
proceeded (as part of the RCT), rather than trying to
reconstruct them retrospectively. To collect utilization
data in the RCT, we developed a process tracking form for
manually recording information on: (1) components
delivered; (2) time spent with each participant to conduct
the intervention or follow-up; (3) materials provided; and
(4) travel times and distances. The costs collected were
those necessary for reproducing the intervention in a non-
research setting [2]. They included: (1) staff time spent to
deliver the intervention; (2) cost of determining environ-
mental nicotine levels (used in MI); (3) cost of training
the nurses to deliver the intervention; and (4) cost of pro-
ducing the self-help materials. The nurses tracked their
resource consumption and time themselves, distinguish-
ing intervention time from research and evaluation time.
Thus, the process tracking form collected the number of
minutes nurses spent contacting participants (scheduling)
and preparing and delivering the intervention (from start
to finish), documented the distance in miles to a partici-
pant's home, and listed the amounts of materials con-
sumed (e.g., the number of pamphlets). It also had space
for notes.
Time spent scheduling and contacting participants is typ-
ically an administrative cost, but we decided that nurses,
rather than clerical staff, should have phone contact with
participants before visiting their homes. The only addi-
tional support required was from a nurse supervisor, who
was trained in delivering the MI intervention but spent lit-
tle effort on the intervention itself.
Invoices for photocopying and other production expenses
were filed by research administrators and used as the
bases for cost estimates and to confirm quantities. Facili-
ties costs (e.g., utilities and custodial services) were
deemed similar in both groups, and therefore excluded.
No new or existing equipment was required.
A significant category of costs was, however, transporta-
tion costs. Participants did not incur travel costs because
they received the intervention at home, but nurses did and
they logged their time spent during travel and the number
of miles to and from participants' homes on the process
tracking form. We did not assume "stacking" of travel
(e.g., a nurse might visit 3-4 houses at one time in a given
community), although a program like this could involve
"stacked travel," with potentially less travel time for out-
reach nurses. While participants did not spend time
traveling to and from the intervention, they did spend
time participating in it. Nurses logged participant time
spent in the intervention, again through the process track-
ing system.
Table 1: Three-way classification of resource utilization and 
costs
Set-Up or Implementation Costs
1. Training Costs
2. Marketing Costs
Time-Dependent Program Costs
1. Administrative Personnel
2. Durable Equipment
3. Program Space
4. Utilities
Variable Program Costs
1. Staff Time
2. Patient/Participant Time
3. Transportation
4. Consumables (e.g., materials)
5. Analysis of Nicotine SamplesBMC Pregnancy and Childbirth 2009, 9:46 http://www.biomedcentral.com/1471-2393/9/46
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For our outreach MI program, mean values for staff time
were: (1) scheduling, 17 min; (2) preparation, 11 min; (3)
intervention delivery, 66 min per session; and (4) travel to
and from the delivery site, 40 min and 29 miles. Average
participant time spent during MI was 66 minutes per ses-
sion (Table 3).
Step 3: Valuing resources
The next step in micro-costing is to value the inputs to the
intervention and then multiply those values by the units
of resource utilization. This generates the total costs over-
all as well as the costs per component for implementing
MI on an outreach basis.
Resource costs
Cost of personnel time
By far the largest cost component for the MI intervention
was personnel time, the primary personnel being nurses.
We used the nurses' actual wages and fringe benefits
(obtained from the clinics' payroll and accounting offices)
to assign a monetary value to personnel time; thus, these
rates would have to be adjusted for interventions outside
the Boston area. The average nurse's salary plus benefits
Table 2: Resource utilization categories and costs
Resource Utilization Components Measurable Units (Q) Resource Valuation (P) Cost per Unit of Consumption
Set-Up or Implementation Costs
Training Staff (Nurses & Supervisor)
Trainer Time Minutes Hourly Wage Rate TC*
Trainer Transportation Miles Cents per Mile TC**
Trainee Time Minutes Salary + Fringe TC*
Trainee Transportation Miles Cents per Mile TC**
Training Manuals Item Production Costs TC
Overheads and Hand-Outs Item Production Costs TC
Refreshments Item Purchased Costs TC
Variable Program Costs
Staff Time (Nurses)
Scheduling Minutes Salary + Fringe TC*
Preparation Minutes Salary + Fringe TC*
Intervention Delivery Minutes Salary + Fringe TC*
Travel Minutes Salary + Fringe TC*
Patient/Participant Time Minutes Hourly Wage Rate TC*
Transportation Miles Cents per Mile TC**
Self-Help Materials Item Production Costs TC
Analysis of Nicotine Samples Samples Lab Costs TC
*(TC = P*Q) product of price (P; salary & fringe or wage rate costs per minute) and quantity (Q; average minutes per person). TC is Total Costs.
**(TC = P*Q) product of price (P; Cents per Mile == $0.25) and quantity (Q; average roundtrip miles)BMC Pregnancy and Childbirth 2009, 9:46 http://www.biomedcentral.com/1471-2393/9/46
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was $31.45 per hour (based on an annual salary of
$50,741 in 1997 dollars plus ~24% for benefits).
The calculations for determining the cost per unit of staff
time are shown in Table 2. Total personnel costs (TCp =
P*Q) were the product of price (P; salary & fringe costs per
minute) and quantity (Q; average minutes per partici-
pant).
Participants' time
The monetary value of the time the participants spent
receiving the MI was estimated by their hourly wage. For
low-income women, we used the minimum wage in 1997
obtained from the Bureau of Labor Statistics (BLS) [15].
Costs of material, supplies, and laboratory tests
Costs of purchasing consumables used in the intervention
were obtained from research administrators. Costs of lab-
oratory tests used to analyze nicotine samples were
recorded, as was the cost of photocopying the self-help
materials.
Future cost savings
Future cost savings associated with smoking cessation and
relapse prevention cannot be determined while a clinical
trial is in progress and therefore must be gross-costed,
using rough estimates from the literature and sensitivity
analysis. These costs were assumed to be zero in the base
case. Published estimates of net lifetime additional medi-
cal costs for smokers are $6,239 (discounted 1990 dol-
lars) [8-10]. Published estimates that include net
smoking-attributable medical costs for neonatal intensive
care, chronic medical conditions, and acute conditions
during the first year of life range from $1,024 to $1,228
[11] (in discounted 1996 dollars). Non-medical net
attributable savings or costs that are associated with early
death from smoking (e.g., social security, long-term care,
etc.) are excluded. These costs are included in the overall
cost analyses reported from the societal perspective, but
are not reported in the following tables of direct program
costs.
Sensitivity analyses
Sensitivity analyses were conducted to analyze the varia-
tion in total costs according to uncertainties in key cost
categories, such as intervention delivery, staff travel, and
analysis of nicotine samples.
Results
Calculating total program costs and cost per participant
Table 4 shows the total cost and per participant cost for
the interventions. All costs were reported in 1997 dollars
and adjusted, when necessary, using the medical care
component of the consumer price index from the BLS. The
main cost components of outreach MI were intervention
delivery, travel time, scheduling, and training.
The total fixed costs of the MI were $3,930 and the total
variable costs of the MI were $44,710. The total cost of the
MI intervention for 156 participants was $48,672 or $312
per participant. The costs and costs per participant of the
individual components were (totals may not add due to
rounding):
Set-up or implementation costs
• Eight-hour training session for the nurses and their
supervisor = $3,930 or $25.2 per MI participant
Table 3: Variable program resource utilization
Resource Components Mean Units per Participant 95% Confidence Interval
Staff Time
Scheduling 17 minutes (14.9 to 19.2) minutes
Preparation 11 minutes (9.7 to 12.7) minutes
Intervention Delivery 66 minutes (63.0 to 68.9) minutes
Travel 40 minutes (37.1 to 43.1) minutes
Patient/Participant Time 66 minutes (63.0 to 68.9) minutes
Transportation 29 miles (25.7 to 31.5) miles
Materials 7 items N/A
Analysis of Nicotine Samples 2 dosimeters N/ABMC Pregnancy and Childbirth 2009, 9:46 http://www.biomedcentral.com/1471-2393/9/46
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Variable program costs
￿ MI Scheduling - 17 minutes on average; @ $0.52/
minute = $8.8 per intervention session or $26.5 per
participant
￿ MI Preparation - 11 minutes on average; @ $0.52/
minute = $5.7 per intervention session or $17.2 per
participant
￿ MI Delivery - 66 minutes on average; @ $0.52/
minute = $34.3 per session or $103 per participant
￿ Travel to and from the intervention delivery site - 40
minutes on average; @ $0.52/minute = $20.8 per visit
or $62.4 per participant
￿ Participant time spent in MI - 66 minutes on average;
@ a minimum wage of $5.15 per hour = $17.0 per
participant
￿ Transportation to and from the MI delivery site for
mileage (29 miles) @$0.25 per mile = $21.8 per par-
ticipant
￿ Printed self-help materials (7 items for the MI group
and 2 for UC group) = $4.7 (MI) per participant and
$1.8 (UC) per participant, a difference of $2.90 per MI
participant
￿ Cost of analyzing a nicotine sample - $17 per sample
= $34 per participant (2 samples analyzed)
The total cost of $311.8 per participant for MI interven-
tion compared with a cost of $4.82 per participant for
usual care, a difference of $307 ([CI], $289.2 to $322.8)
(Table 4). Using the expected fixed cost ($3,930) and var-
iable cost per participant ($287) as a guide, one is then
able to estimate the cost of providing MI to greater or
lesser numbers of participants. For example, the total
Table 4: Direct program cost components of MI and UC
Mean Cost per Participant
Cost Components MI UC Cost Difference (95% CI)
Set-Up or Implementation Costs
Training Staff ($3,930 for MI) $25.2 $0 $25.2
Variable Program Costs
Staff Time
Scheduling $26.5 $0 $26.5 ($23.7 to $29.3)
Preparation $17.2 $0 $17.2 ($15.1 to $18.9)
Intervention Delivery $103.0 $2.6 $100.4 ($95.7 to $104.8)
Travel $62.4 $0 $62.4 ($56.8 to $66.3)
Patient/Participant Time $17.0 $0.42 $16.6 ($15.8 to $18.2)
Transportation $21.8 $0 $21.8 ($18.7 to $23.5)
Materials $4.7 $1.8 $2.9
Analysis of Nicotine Samples $34.0 $0 $34.0
Total Variable Costs $286.6 $4.82 $281.8 ($264 to $298)
Total Costs $311.8 $4.82 $307 ($289.2 to $322.8)BMC Pregnancy and Childbirth 2009, 9:46 http://www.biomedcentral.com/1471-2393/9/46
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expected program costs for delivering MI to 500 partici-
pants (Fixed cost + 500 * Variable cost) would be $3,930
+ 500 * 287 or $147,430. This assumes no economies of
scale in delivering the program such that fixed costs will
decrease in the long run.
Sensitivity analyses
We conducted sensitivity analyses to examine the varia-
tion in our total cost estimates as a result of variation in
key parameters. We were most interested in examining the
effects of uncertainties in key cost categories for MI: inter-
vention delivery, staff travel, and analysis of nicotine sam-
ples. As shown in Table 5, we varied the intervention
delivery costs to a 25% decrease and increase, resulting in
a range of total costs from $286 to $338. For staff travel,
we reduced and increased the costs by 30% resulting in a
range of total cost per person of $293 to $331. Finally,
decreasing and increasing the costs of analyzing the nico-
tine samples by 35% resulted in a range of total costs per
person of $300 to $324.
Discussion
This study's aim was to develop a methodology and to
measure and report the cost of outreach MI programs for
smoking cessation and relapse prevention. The methodol-
ogy offered here systematically applies the micro-costing
framework recommended by the Panel for Cost-Effective-
ness in Medicine in 1996 [2,16], but extends it through
operationalizing costing techniques for an outreach pro-
gram grounded in economic theory. It can be used, with
minimal modifications, to estimate the costs of similar
behavioral interventions, especially those that rely heavily
on staff time and are outreach in nature. The process track-
ing system may be especially useful for collecting costs
when training, delivery, scheduling, and travel are signifi-
cant cost components.
Micro-costing using a process tracking system has many
strengths and some limitations. The strengths include: 1)
its systematic nature; 2) standardization across cost com-
ponents; 3) reliability and validity resulting from cost col-
lection during actual program delivery; and 4) ability to
account for the most significant inputs (provider and par-
ticipant time spent in training, scheduling, preparation,
delivery, and travel). It is akin to detailed cost-accounting
using the principles of industrial engineering and time-
motion studies to estimate and compare actual produc-
tion costs [17-22]. One limitation is the method's reliance
on self-observation by providers, which may be prone to
error. The alternatives--direct observation by a trained
observer and patient flow analysis [23] --also have limita-
tions, however, and each is susceptible to human error as
well. Patient flow analysis is particularly problematic in
that it places the burden for documentation and accuracy
of reporting on the participant involved in the interven-
tion. This method seems less desirable because it detracts
from both the overall accuracy of data collection and
intervention efficacy. Another limitation to micro-costing
is the substantial burden it places on the research team
and intervention personnel. Like the CCC's Cost Alloca-
tion Methodology [24], noted by the ADSS (Alcohol and
Drug Services Study) Cost Study [25], micro-costing is a
highly detailed and intensive method. Finally, limitations
exist (e.g., differences in recruitment costs, scheduling
issues, etc.) in translating cost estimates obtained through
a randomized controlled trial to real world clinical prac-
tice.
There are other substance use treatment costing methods,
such as the use of the Drug Abuse Treatment Cost Analysis
Program (DATCAP) [26], and Substance Abuse Services
Cost Analysis Program (SASCAP) [27]. However, these
instruments tend to focus primarily on the institutional
level in inpatient and outpatient treatment programs [28-
32], aggregating and generalizing over the site of care
delivery for typical costs of services. For the specific pur-
poses of this study, they are less appropriate due to the use
of integrated services such as behavioral counseling and
due to the need to cost in detail these promising treatment
services in conjunction with a randomized controlled
trial. In this study, rather, we aimed to employ micro-cost-
ing to reflect the ideal of identification, measurement, and
valuation of resources, guided by a theoretical framework
that identifies all consequences of adopting different
interventions.
Table 5: Sensitivity analyses
Resource Uncertainties Examined Total Cost per Participant
Staff Time
Intervention Delivery +/- 25% ($286 to $338)
Travel +/- 30% ($293 to $331)
Analysis of Nicotine Samples +/- 35% ($300 to $324)BMC Pregnancy and Childbirth 2009, 9:46 http://www.biomedcentral.com/1471-2393/9/46
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Thus, despite the noted limitations, the detailed cost
information collected by this methodology is essential for
understanding the levels and types of resources necessary
for effective implementation of smoking cessation and
relapse prevention programs. As an input to cost-effective-
ness analyses [33] and cost-benefit analyses, it could ena-
ble benefits to be weighed against costs to facilitate
rational allocation decisions. Effective policy analysis and
implementation of medical and public health programs
relies on valid and reliable estimates of the costs and ben-
efits of such programs. Micro-costing can help in provid-
ing these cost estimates. The methodology could help
improve collection of accurate data on costs and estimates
of the real resource costs of interventions alongside clini-
cal trials and improve the validity and reliability of esti-
mates of resource costs for interventions targeted at
underserved and hard-to-reach populations.
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